Background: Ketamine is routinely used in operating theatres, emergency departments, ICUs, and even outpatient units. Despite the widespread use of ketamine, only basic aspects of its interactions with inhalation anaesthetic agents are known, and formal testing of interactions in humans is lacking. The minimum alveolar concentration (MAC) of inhalation anaesthetics is used to guide the depth of anaesthesia, and several drugs are known to influence the MAC. The aim of this study was to investigate whether intravenous application of ketamine influences the MAC of sevoflurane in humans. Methods: Adult patients undergoing elective surgery were included in this randomised, double-blinded, placebocontrolled study. Patients were assigned to one of three groups, each of which received a bolus of placebo, 0.5 mg kg À1 S-
Ketamine is an intravenous anaesthetic drug that has been used globally in the battlefield and for the sedation of uncooperative children for decades. In recent years, ketamine has gained more clinical attention, and it is now routinely used in operating theatres, emergency departments, and ICUs. Ketamine is also used in outpatient units for those suffering from chronic pain or depression. 1 The main action of ketamine is non-competitive antagonism at N-methyl-D-aspartate (NMDA) receptors. NMDA receptors modulate nociception and are involved in the development of chronic pain syndromes. 2 In the operating theatre, ketamine is commonly used as 'an adjunct on top of volatile opioid-based anaesthesia for analgesic and anti-inflammatory reasons'. 3 Knowledge about the interaction of ketamine with these anaesthetic agents is therefore essential to providing safe anaesthesia. The most common guidance method for the depth of anaesthesia is the minimal alveolar concentration (MAC). MAC is defined as the minimum alveolar concentration of an anaesthetic that prevents movement in response to a noxious stimulus in 50% of subjects. 4 MAC is decreased by various drugs, such as opioids, benzodiazepines, propofol, lidocaine, and clonidine. 5, 6 However, despite the widespread use of ketamine, studies on its effect on the MAC in humans are lacking. Therefore, the primary aim of this study was to investigate whether ketamine decreases the MAC of sevoflurane in healthy adult individuals undergoing elective surgery.
Methods
This study was performed in accordance with the ethical standards stated in the Declaration of Helsinki. The CONSORT (Consolidated Standards of Reporting Trials) guidelines were used to guide the preparation of this article. We conducted this single-centre, prospective, randomised, controlled, 
Study population
Adult patients with an American Society of Anesthesiologists (ASA) physical status of 1e3 who were scheduled for elective surgery requiring a skin incision of at least 3 cm at the trunk were eligible for enrolment in the study. Surgery had to be feasible under general anaesthesia with a laryngeal mask airway (LMA). As a consequence, we recruited female patients undergoing breast surgery or inguinal hernia repair with a size of skin incision ranging from 3 to 15 cm. Age was restricted to 30e65 yr because MAC has been shown to be age-dependent and the difference in the MAC between 30 and 65 yr is limited to approximately 20%. 7 Patients unable to understand the study procedure or unable to give informed consent, with concurrent analgesic or sedative medication, with history of chronic pain, psychiatric disorders, or alcohol or drug abuse, with an allergy to the study medication, who were pregnant or breastfeeding, with existing contraindications for inhalation induction, or with a BMI >30 and <18 kg m À2 were excluded from the study.
Study design, randomisation, and blinding
Subjects were randomly assigned to one of three groups: the placebo group, the low-dose ketamine group, and the highdose ketamine group. Randomisation was performed via block randomisation with blocks of 30 using a computerderived randomisation list. Randomisation envelopes containing the study medication data were prepared. The envelopes were opened by the study nurse preparing the study medication immediately before the patient arrived in the operating theatre. All other investigators and all subjects were blinded to the study medication.
The study medication was administered in a bolus injected over 30 s after insertion of the LMA, followed by continuous infusion, which started after the initial bolus. The placebo group received a bolus of 0.9% saline, followed by continuous infusion of 0.9% saline. The low-dose ketamine group was administered a bolus of 0.5 mg kg À1 S-ketamine in saline, followed by 0.5 mg kg À1 h À1 S-ketamine in saline, whereas the high-dose ketamine group was administered a bolus of 1 mg kg À1 S-ketamine in saline, followed by continuous infusion of 1 mg kg À1 h À1 S-ketamine in saline. The syringes and infusions were identical for all of the groups and were run at the same rate in all subjects to enable blinding of the investigators.
Anaesthesia
Routine anaesthetic monitoring consisted of pulse oximetry, electrocardiography, blood pressure, and the bispectral index (BIS). The Model A-2000 software version 3.3 BIS monitor (Aspect Medical Systems, Norwood, MA, USA) with an averaging window of 15 s was used. In addition, body temperature was measured using a probe in the nasopharynx, and forced air was applied to the lower limbs to maintain normothermia. The patients did not receive any preoperative sedative medication. Anaesthesia was induced by multiple deep inhalation breaths of 8% sevoflurane in 100% oxygen. 8 Once the BIS decreased below 40 and the patients were adequately clinically sedated, an LMA was inserted, and the patients' lungs were ventilated with 100% oxygen at a fresh-gas flow of 6 L min À1 . 9 Tidal volumes were set to 6 to 8 ml kg À1 at a frequency of 10 to 16 breaths per minute to achieve normocapnia (endtidal CO 2 : 3.99e5.33 kPa). The end-tidal (ET) concentration of sevoflurane was measured using a Primus monitor with an accuracy of 0.1% (Dr€ ager, Lü beck, Germany). The ET sevoflurane concentration was increased or decreased to a predefined level and held constant for at least 15 min before the
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skin incision was performed to allow for adequate equilibration. 10 After induction of anaesthesia, the study medication was administered according to the study group assignment.
Determination of MAC
For the estimation of MAC, we used an 'up-and-down' titration method as described. 6, 11 For each group, the ET sevoflurane concentration of the first patient was 1.6%. The ET sevoflurane concentration in the subsequent patient in each group was increased by 0.2% if the previous patient had moved in response to the skin incision. The ET sevoflurane concentration in the subsequent patient was decreased by 0.2% if the previous patient had not moved in response to the skin incision. Adjustment of the ET sevoflurane concentration was continued in all subsequent patients in each group, and the ET sevoflurane concentration was held constant for at least 15 min before the skin incision was performed. 10 The MAC was determined by evaluating the motor response to the initial skin incision. Investigators blinded to both the study group and the ET sevoflurane concentration were positioned at the patient's head and arms and at the patient's legs to assess motor response to the skin incision. Reaction to skin incision was classified as movement or no movement. Response to the skin incision was deemed 'movement' if a gross, purposeful movement of the head or at least one extremity was observed within 1 min after the skin incision. 4 Coughing, bucking, and straining were not considered movement.
After the response to the skin incision was assessed, infusion of the study medication was stopped, and the patients received an i.v. bolus of 2e3 mg kg À1 fentanyl. Furthermore, the sevoflurane delivery was adjusted to maintain a sevoflurane level equivalent to 0.7e1.2 MAC. Further anaesthetic management was based on our departmental standard, which includes the intraoperative administration of non-opioid analgesics (i.e. metamizole) and medical prophylaxis of postoperative nausea and vomiting (i.e. ondansetron). Piritramide was used as the first-line agent for pain control in the recovery area.
Secondary end-point parameters
Values of non-invasive arterial blood pressure, heart rate (HR), and BIS were recorded every 2 min throughout the study period and until 2 min after skin incision. An arterial blood sample was taken at the time the skin incision was performed to determine the blood concentrations of S-ketamine. After surgery and in the recovery area, patients were asked about their pain level on a numeric rating scale, and about the presence of intraoperative awareness, nausea, vomiting, and hallucinations.
Measurement of plasma ketamine concentrations
For the quantification of ketamine plasma concentrations, 100 ml plasma was mixed with 10 ml internal standard solution (25 mg ketamine ml À1 methanol) and 100 ml phosphate buffer pH 7.4 saturated with saline and was extracted with 200 ml ethyl acetate. The sample was vortexed for 1 min and centrifuged at 16 400 Â g. Next, 100 ml supernatant was transferred into a gas chromatography-mass spectrometry (GC-MS) vial and evaporated and subsequently reconstituted into 25 ml ethyl acetate.
The analyses were performed using GC-MS (7000 C GC/MS triple Quad; Agilent, Santa Clara, CA, USA) in scan mode. Then, 1 ml of the solution was injected into an Agilent J&W HP-5 MS column (30 m, 0.25 mm, 0.25 mm). The calibration range used for the quantitative analysis was 0.2e10 mg ml
À1
. The evaluation was performed with MassHunter MS Quantitative Analysis software (Agilent). 
Statistical analysis
The primary end point was the MAC of sevoflurane. Choi's 12 method was used for the calculation of the MAC estimators of sevoflurane, as this method has been shown to perform well relative to other estimators for up-and-down designs. We also calculated the corresponding bootstrap estimates and confidence intervals (CIs). Bootstrap estimates were calculated using 5000 bootstrap samples. As there is no statistical test providing a P-value available for comparison of the MAC estimates, 95% CIs were used for the interpretation of statistical significance.
Secondary end pointsdincluding baseline characteristics, time between indication of anaesthesia and skin incision, plasma ketamine concentration, and perioperative measurements, such as heart rate, blood pressure, and BISdwere compared between groups using the c 2 test or one-way analysis of variance (ANOVA), and P-values were adjusted for multiplicity using Bonferroni correction as there are three groups involved. Adjusted P-values of <0.05 were considered statistically significant. The analyses were performed using R (R: A Language and Environment for Statistical Computing, R Core Team, R Foundation for Statistical Computing, Vienna, Austria 2014, https://www.R-project.org) and SPSS 25 (SPSS Statistics, IBM, Armonk, NY, USA). The data are presented as mean (standard deviation, SD), unless indicated otherwise.
Based on data from previous studies, a minimum number of 14 subject per group was needed to detect a 30% reduction of the MAC of sevoflurane between the placebo and high-dose ketamine groups at a significance level of 0.05 and with a power of 80%. 6 Based on our previous experience with the upand-down titration method, we increased the number of subjects to 20 per group because we did not observe a perfect sequence of response/non-response for the titration process in the past.
6,11
Results
Sixty-seven female subjects were recruited for our study. Six of these patients did not participate in the study for organisational reasons. One subject did not complete the study because of difficulties in placing the LMA after inhalation induction. This subject was replaced by the consecutive subjects. Sixty subjects completed the study procedure (Fig. 1) .
The subject characteristics and morphometric data did not differ between the three study groups ( Table 1) . The mean time between the insertion of the LMA and the skin incision for all subjects was 19 (4) min, allowing for development of an adequate steady-state of end-tidal sevoflurane.
Primary outcome
The MAC of sevoflurane was significantly reduced by S-ketamine (Fig. 2) . The bootstrap estimate of the MAC of sevoflurane was 2.2 (0.1)% (95% CI, 2e2.4%) in the placebo group, 0.9 (0.1)% (95% CI, 0.8e1.1%) in the low-dose ketamine group, and 0.5 (0.1)% (95% CI, 0.4e0.8%) in the high-dose ketamine group.
The MAC in the high-and low-dose ketamine groups was therefore significantly lower than that of the placebo group, and the MAC in the high-dose ketamine group was significantly lower than the MAC in the low-dose ketamine group. The mean difference between the MAC in the placebo group and that of the low-dose ketamine group was e1.3% sevoflurane, yielding a relative reduction in the MAC of approximately 59%. The mean difference between the MAC in the placebo group and that of the high-dose ketamine group was e1.7% sevoflurane, which is a relative reduction in the MAC by approximately 77%. The mean difference between the point estimator of the MAC in the low-dose ketamine group and that in the high-dose ketamine group was e0.4% sevoflurane, resulting in a relative reduction in the MAC by approximately 44%.
Secondary outcome parameters
Ketamine was not detected in the plasma of patients in the placebo group. The average plasma ketamine concentration was 0.5 (0.2) mg ml À1 (95% CI, 0.4e0.6 mg ml À1 ) in the low-dose ketamine group and 1.1 (1.0) mg ml À1 (95% CI, 0.6e1.6 mg ml À1 ) in the high-dose ketamine group (P¼0.023).
The mean BIS values before and after skin incision were significantly lower in the placebo group compared with that in the low-dose ketamine group and high-dose ketamine group. There were also significant differences in systolic blood pressure between the placebo and the low-dose ketamine groups before and after skin incision.
No differences in heart rate were found between the groups. A detailed analysis of the BIS, heart rate, and blood pressure in the study groups is presented in Table 2 .
The mean reported pain score on a numeric rating scale in the recovery area was 1.7 (sd 1.4) in the placebo group, 1.8 (1.5) in the low-dose ketamine group, and 2.8 (1.9) in the high-dose ketamine group, and there were no significant differences between the groups (overall P¼0.11). No signs of awareness were reported in any of the groups. Postoperative nausea was not reported by any subjects in the placebo group or in the lowdose ketamine group, but it was reported by two patients in the high-dose ketamine group. None of the subjects reported having postoperative vomiting. No psychedelic side-effects were observed in the placebo group or in the low-dose ketamine group. However, one subject in the high-dose ketamine group reported having 'weird dreams,' but she did not feel annoyed by them.
Discussion
In this prospective, randomised, controlled, double-blinded study, we assessed whether intravenous administration of ketamine influences the MAC of sevoflurane in ASA 1e3 females undergoing elective surgery. We report a significant reduction in the MAC of sevoflurane after administration of Sketamine in adult females. The reduction in the MAC of sevoflurane was dose-dependent, with a relative reduction in MAC of up to 76% in the high-dose ketamine group.
To our knowledge, this is the first study on the influence of S-ketamine on the MAC of volatile anaesthetics in humans. A significant dose-dependent reduction in the MAC of volatile anaesthetics by ketamine has been reported in several animal studies.
13e19 Only a few animal studies have specifically studied the effect of ketamine on the MAC of sevoflurane, and a MAC reduction of 41e57% was reported. 17e19 Although the plasma concentration of ketamine was significantly higher in the study reporting the highest MAC reduction of 57%, the MAC reducing effect in that study was less pronounced compared with that in our study. 19 A possible explanation for this finding is that we used the S(þ)-enantiomer of ketamine instead of the R(e)eS(þ) racemic mixture of ketamine, which was used in the animal study. S(þ)-ketamine has been shown to be twice as potent compared with the racemic mixture of ketamine, which could explain a larger effect on the MAC despite lower plasma ketamine concentrations. 20 However, the MAC of an inhalation anaesthetic may vary up to 20% among different species, which limits direct comparisons 21 In addition, we observed significant variation in the measured ketamine plasma concentrations in our study, which also limits comparability.
Based on the results of our study, the MAC reducing effect of ketamine was dose-dependent, and this finding has also been found in published studies on animals. 14, 17, 19, 22 Pypendop and colleagues 22 found a sigmoid relationship of ketamine on the MAC immobility of enflurane in dogs, with ketamine having a maximum MAC reducing effect of 92%. Such a ceiling effect suggests a synergistic effect of ketamine on volatile anaesthetics. However, our data do not allow firm conclusions to be drawn about ketamine having a synergistic or an additive effect on the MAC of sevoflurane, as we did not include a group of patients anaesthetised purely with ketamine to determine the C50 of ketamine in supressing the motor response to skin incision. In our study, the BIS was significantly higher in the ketamine groups than in the placebo group. This finding suggests a relevant effect of ketamine on the BIS in patients exposed to sevoflurane anaesthesia. An increase in BIS of 10% after a bolus dose of 0.5 mg kg À1 ketamine has been reported in the literature. 23 However, in our study, the BIS in the ketamine groups was roughly twice as high as that in the placebo group, and the substantially lower sevoflurane concentrations in the ketamine groups likely contributed to this finding. There were no significant differences regarding postoperative pain, awareness, nausea, vomiting, and psychedelic side-effects found between the groups. No differences in haemodynamic parameters were observed, except for a difference in systolic blood pressure between the placebo and the low-dose ketamine group 2 min after the skin incision. However, it is important to note that anaesthetic management, after the response to skin incision was determined, was left to the discretion of the individual anaesthetist, which might have affected these results.
A limitation of this study is that the study population consisted of only female patients, which limits the generalisability of the findings from this trial. However, another prospective trial did not find evidence of a difference in the MAC between women and men. 24 Another limitation is that we were not able to examine the effect of ketamine on sevoflurane across the entire range of doses and preparations used clinically. There is large variation in doses of adjunctive ketamine in the perioperative setting, ranging from boluses of 0.06e1 mg kg À1 , which are often combined with infusions at rates from 0.002 to 0.6 mg kg À1 h À1 . 25, 26 Furthermore, the design of our study did not allow for estimation of the MAC 95/99, which is when 95% and 99% of patients do not respond to a noxious stimulus. As the MAC 95 or 99 might be more important for clinical practice, this should be considered a limitation of our study.
The relatively small sample size used in our study might also be considered a limitation, as it has been shown that a sample size of more than 20 would be needed to produce stable MAC estimates. 27 However, another study did not find additional improvement of MAC estimates if the number of crossovers was increased to more than six. 28 Despite these limitations, the findings of our study are of clinical importance because sevoflurane was found to be the most commonly used anaesthetic agent for general anaesthesia in a 2013 survey and because ketamine at doses similar to those used in our study is routinely used as an adjunct to general anaesthesia.
25e29 Thorough knowledge about the interaction of these anaesthetic agents is therefore essential for everyday clinical practice. Further research to investigate how ketamine affects other important end points of sevoflurane-based anaesthesia, such as the MAC 95/99, unconsciousness, and the adrenergic response is needed to optimise patient care.
In conclusion, the intraoperative administration of doses of S-ketamine used clinically, 0.5 and 1 mg kg À1 , significantly reduced the MAC of sevoflurane in humans. The reduction in MAC of sevoflurane appears to be dose-dependent, with a relative reduction by 59% in the low-dose ketamine group and 77% in the high-dose ketamine group in adult females.
